Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Abpro Bio Co., Ltd.
  6. News
  7. Summary
    A195990   KR7195990007

ABPRO BIO CO., LTD.

(A195990)
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Abpro Bio Co., Ltd. announced that it expects to receive KRW 4.99999895 billion in funding

10/14/2021 EST

Abpro Bio Co., Ltd. announced a private placement of 4,587,155 shares at the price of KRW 1,090 per share for gross proceeds of KRW 4,999,998,950 on October 14, 2021. The transaction will include participation from Wonjin Partners Co., Ltd. The shares will have restriction for 1 years. The face value of shares is KRW 500 per share. The method of issuance is third party allotment method. The board of directors of the company has approved the transaction. The transaction is expected to close on December 29, 2021.


ę S&P Capital IQ 2021
All news about ABPRO BIO CO., LTD.
2022Abpro Bio Co., Ltd. (KOSDAQ:A195990) cancelled the acquisiti..
CI
2022Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.91..
CI
2021Abpro Bio Co., Ltd. announced that it has received KRW 5.999999552 billion in funding
CI
2021Abpro Bio Co., Ltd. announced that it expects to receive KRW 4.99999895 billion in fund..
CI
2021Abpro Bio Co., Ltd. announced that it has received KRW 15 billion in funding from Merit..
CI
2021Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from..
CI
2020KUKBO Logistics Co.,Ltd acquired 19.35% stake in Bog International Co., Ltd. from Abpro..
CI
2020Hwail Pharmaceutical Co.,Ltd. announced that it has received KRW 16.4999812 billion in ..
CI
2020Abpro Bio Co., Ltd. announced that it has received KRW 10 billion in funding from Korea..
CI
2020Hwail Pharmaceutical Co.,Ltd. announced that it expects to receive KRW 16.4999812 billi..
CI
More news
Financials
Sales 2021 32 914 M 26,7 M 26,7 M
Net income 2021 -10 030 M -8,13 M -8,13 M
Net cash 2021 32 581 M 26,4 M 26,4 M
P/E ratio 2021 -22,3x
Yield 2021 -
Capitalization 116 B 94,1 M 94,1 M
EV / Sales 2020 8,97x
EV / Sales 2021 6,42x
Nbr of Employees 50
Free-Float 90,5%
Chart ABPRO BIO CO., LTD.
Duration : Period :
Abpro Bio Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABPRO BIO CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Pui Chan Ian Yan Co-Chief Executive Officer & Director
Jin-Sang Yang Co-Chief Executive Officer & Director
Jae-Hong Jeon Independent Director
Gab-Jin Kang Independent Director
Ki-Chul An Independent Director